HCG reports robust Q3 & 9M FY26 growth, strengthening its lead in Indian oncology
HCG clinicians contributing to one of the largest bodies of oncology research from India
HCG clinicians contributing to one of the largest bodies of oncology research from India
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
Subscribe To Our Newsletter & Stay Updated